pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
romla 25 mg/g + 25 mg/g krém
magnapharm sk, slovensko - amidy, kombinácie - 01 - anaesthetica (lokÁlne)
infectoscab 5 % krém
infectopharm arzneimittel und consilium gmbh, nemecko - permetrín - 25 - antiparasitica (antiprotozoica, antimalarica)
iblias
bayer ag - octocog alfa - hemofília a - antihemoragiká - liečba a profylaxia krvácania u pacientov s hemofíliou a (vrodená deficiencia faktora viii). iblias môžu byť použité pre všetky vekové skupiny.
darzalex
janssen-cilag international n.v. - daratumumab - viacnásobný myelóm - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinácii s bortezomib, talidomid a dexamethasone na liečbu dospelých pacientov s novo diagnostikovanou myelómom je mladších, ktorí majú nárok na autológne transplantácii kmeňových buniek. v kombinácii s lenalidomide a dexamethasone, alebo bortezomib a dexamethasone, na liečbu dospelých pacientov s mnohopočetným myelómom, ktorí dostali aspoň jeden pred terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. ako monotherapy na liečbu dospelých pacientov s relapsed a žiaruvzdorné myelómom je mladších, ktorých pred terapia súčasťou proteasome inhibítor a imunomodulačné agent a ktorí preukázali progresii ochorenia na poslednej terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
aminoven 15 %
fresenius kabi ab, Švédsko - aminokyseliny - 76 - infundibilia
propofol mct/lct fresenius 20 mg/ml injekčná/infúzna emulzia
fresenius kabi deutschland gmbh, nemecko - propofol - 05 - anaesthetica (celkovÉ)
propofol mct fresenius 20 mg/ml injkečná/infúzna emulzia v naplnenej injekčnej striekačke
fresenius kabi deutschland gmbh, nemecko - propofol - 05 - anaesthetica (celkovÉ)
abakavir/lamivudín vale 600 mg/300 mg
mylan s.a.s., francúzsko - lamivudín a abakavir - 42 - chemotherapeutica (vratane tuberkulostatik)